Gastric Cancer

Papers
(The TQCC of Gastric Cancer is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)207
Current status of immune checkpoint inhibitors for gastric cancer123
Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial75
Open versus minimally invasive total gastrectomy after neoadjuvant chemotherapy: results of a European randomized trial74
Apatinib induced ferroptosis by lipid peroxidation in gastric cancer69
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial63
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors62
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab57
LncRNA HOTAIR promotes the growth and metastasis of gastric cancer by sponging miR-1277-5p and upregulating COL5A156
A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010)52
Endoscopic three-categorical diagnosis of Helicobacter pylori infection using linked color imaging and deep learning: a single-center prospective study (with video)43
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy42
RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription38
Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-0734
Artificial intelligence-based diagnosis of upper gastrointestinal subepithelial lesions on endoscopic ultrasonography images34
ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer34
Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial32
Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors32
Deep learning system for lymph node quantification and metastatic cancer identification from whole-slide pathology images32
Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer31
Multicenter prospective trial of total gastrectomy versus proximal gastrectomy for upper third cT1 gastric cancer30
Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models30
Landscape of EBV-positive gastric cancer29
A deep learning method for delineating early gastric cancer resection margin under chromoendoscopy and white light endoscopy29
Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)27
Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort27
Epstein–Barr virus-associated gastric cancer: disease that requires special approach27
Oral nutritional supplements versus a regular diet alone for body weight loss after gastrectomy: a phase 3, multicenter, open-label randomized controlled trial26
Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer26
Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma25
Uptake and tumor-suppressive pathways of exosome-associated GKN1 protein in gastric epithelial cells25
Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling25
Optimized PD-L1 scoring of gastric cancer25
Hospital volume following major surgery for gastric cancer determines in-hospital mortality rate and failure to rescue: a nation-wide study based on German billing data (2009–2017)24
Mitochondrial GRIM-19 deficiency facilitates gastric cancer metastasis through oncogenic ROS-NRF2-HO-1 axis via a NRF2-HO-1 loop24
Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer23
Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based 23
Assessment of diagnostic value of fluorescent lymphography-guided lymphadenectomy for gastric cancer23
Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia23
Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways22
Autophagy induced by Helicobacter pylori infection is necessary for gastric cancer stem cell emergence22
Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy22
A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics22
Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma22
Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance22
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma21
Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer21
CAF promotes chemoresistance through NRP2 in gastric cancer21
Development and validation of a deep learning system for ascites cytopathology interpretation21
Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years21
Long-term persistence of gastric dysbiosis after eradication of Helicobacter pylori in patients who underwent endoscopic submucosal dissection for early gastric cancer20
Association of surgeon and hospital volume with postoperative mortality after total gastrectomy for gastric cancer: data from 71,307 Japanese patients collected from a nationwide web-based data entry 20
Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study20
Comparison between endoscopic submucosal resection and surgery for the curative resection of undifferentiated-type early gastric cancer within expanded indications: a nationwide multi-center study20
Prognostic value of postoperative C-reactive protein elevation versus complication occurrence: a multicenter validation study20
Cathepsin L promotes angiogenesis by regulating the CDP/Cux/VEGF-D pathway in human gastric cancer19
Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis19
Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective19
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer18
Hypoxia associated lncRNA HYPAL promotes proliferation of gastric cancer as ceRNA by sponging miR-431-5p to upregulate CDK1418
EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein–Barr virus-associated gastric cancer18
Safe implementation of robotic gastrectomy for gastric cancer under the requirements for universal health insurance coverage: a retrospective cohort study using a nationwide registry database in Japan18
Association between triglyceride-glucose index and gastric carcinogenesis: a health checkup cohort study18
Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer17
Promising aberrant DNA methylation marker to predict gastric cancer development in individuals with family history and long-term effects of H. pylori eradication on DNA methylation17
Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer17
A novel combination of serum microRNAs for the detection of early gastric cancer16
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer16
Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast16
Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers: a prospective nationwide multicenter study16
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers16
EPRS/GluRS promotes gastric cancer development via WNT/GSK-3β/β-catenin signaling pathway16
Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma16
Clinical significance of endoscopic ultrasonography in diagnosing invasion depth of early gastric cancer prior to endoscopic submucosal dissection16
Preoperative risk factors for postoperative intra-abdominal infectious complication after gastrectomy for gastric cancer using a Japanese web-based nationwide database16
Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit16
Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)16
Crosstalk between WNT and STAT3 is mediated by galectin-3 in tumor progression15
Interleukin-17A derived from mast cells contributes to fibrosis in gastric cancer with peritoneal dissemination15
Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry15
Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis 15
LRRC8A influences the growth of gastric cancer cells via the p53 signaling pathway15
Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—what is currently known?15
Mucin expression in gastric- and gastro-oesophageal signet-ring cell cancer: results from a comprehensive literature review and a large cohort study of Caucasian and Asian gastric cancer14
HDAC6/HNF4α loop mediated by miR-1 promotes bile acids-induced gastric intestinal metaplasia14
Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study14
The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration14
Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases14
Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells14
Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway14
Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer14
Integrin β1 orchestrates the abnormal cell-matrix attachment and invasive behaviour of E-cadherin dysfunctional cells14
Convergent dysbiosis of gastric mucosa and fluid microbiome during stomach carcinogenesis14
Histological diversity and molecular characteristics in gastric cancer: relation of cancer stem cell-related molecules and receptor tyrosine kinase molecules to mixed histological type and more histol13
Indolent feature of Helicobacter pylori-uninfected intramucosal signet ring cell carcinomas with CDH1 mutations13
A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013)13
The incidences of metachronous multiple gastric cancer after various types of gastrectomy: analysis of data from a nationwide Japanese survey13
CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL613
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial13
Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis13
SHARPIN stabilizes β-catenin through a linear ubiquitination-independent manner to support gastric tumorigenesis13
SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence12
Nationwide cohort study: cholesterol level is inversely related with the risk of gastric cancer among postmenopausal women12
Tumorigenic mechanisms of estrogen and Helicobacter pylori cytotoxin-associated gene A in estrogen receptor α-positive diffuse-type gastric adenocarcinoma12
Characteristic endoscopic findings of gastric adenocarcinoma of fundic-gland mucosa type12
Preservation of hepatic branch of the vagus nerve reduces the risk of gallstone formation after gastrectomy12
Gastric equivalent of the ‘Holy Plane’ to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson’s historic schema12
Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer12
Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial12
0.030513048171997